Aarti Pharmalabs
- P/E
- 39.41
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 10.70%
- Debt to Equity
- 0.35
- EPS (TTM)
- ₹23.51
- Book Value
- ₹248.65
- Market Cap
- —
- P/E (TTM)
- 39.41
- P/B
- 3.73
- ROE
- 8.59%
- Dividend Yield
- 0.38%
- EBITDA
- ₹379 Cr
- 52W High
- ₹1,002.40
- 52W Low
- ₹585.00
- Day Range
- ₹912.60 – ₹934.50
- Volume
- 3,52,298
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Aarti Pharmalabs (this company) | ₹926.50 | 39.41 | ₹8,311 Cr | 3.73 | 0.38% | 8.59% | 10.70% | ₹1,969 Cr | ₹213 Cr |
| Median 8 companies | ₹1,587.70 | 39.11 | ₹1,25,337 Cr | 4.57 | 0.48% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 39
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 52
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 17
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 28
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 60
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
3- Stock is trading at 3.73 times its book value
- Company has a low return on equity of 11.9% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.44%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 6 | 12 |
| Oscillators | Bullish | 1 | 6 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 57.47
- Neutral
- MACD (12,26,9)
- 7.51
- Bullish
- SMA (50)
- 874.36
- Bullish
- SMA (200)
- 750.21
- Bullish
As of
Analyst Rating
0 of 1 analyst rates Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | Zero base |
|---|---|
| 3Y | −2.21% |
| 1Y | −14.00% |
| TTM | +1.18% |
Net profit
| 5Y | Zero base |
|---|---|
| 3Y | −3.21% |
| 1Y | −35.66% |
| TTM | −20.22% |
Operating cash flow
| 5Y | Zero base |
|---|---|
| 3Y | +1.58% |
| 1Y | −20.61% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | No sales |
|---|---|
| 3Y | +2.71 pp |
| 1Y | −1.74 pp |
| TTM | −2.16 pp |
Revenue by year
| Mar 2021 | ₹0.00 Cr |
|---|---|
| Mar 2022 | ₹1,200 Cr |
| Mar 2023 | ₹1,945 Cr |
| Mar 2024 | ₹1,853 Cr |
| Mar 2025 | ₹2,115 Cr |
| Mar 2026 | ₹1,819 Cr |
Net profit by year
| Mar 2021 | ₹0.00 Cr |
|---|---|
| Mar 2022 | ₹122 Cr |
| Mar 2023 | ₹193 Cr |
| Mar 2024 | ₹217 Cr |
| Mar 2025 | ₹272 Cr |
| Mar 2026 | ₹175 Cr |
Analyst Forecasts
Analyst consensus here uses a different definition from reported ebitda (they differ 8.8× on periods where both exist), so the forecast is shown on its own rather than joined to the reported line.
AI Analysis — Bull vs Bear
Aarti Pharmalabs Ltd is a healthcare company with a market cap of ₹6,378 Cr trading at a PE of 36.7x. The company is experiencing a significant earnings contraction with TTM profit declining 35% and sales declining 14%, while its 3-year stock CAGR of 25% reflects prior momentum that has reversed sharply with a -22% return over the last year.
- 3-year stock CAGR of 25% indicates strong medium-term wealth creation for earlier investors despite recent correction
- 5-year average ROE of 13% suggests the business has historically generated reasonable returns on shareholder equity
- 3-year average ROE of 12% remains above cost of equity for most Indian companies, indicating underlying business quality
- Market cap of ₹6,378 Cr provides reasonable scale and liquidity for institutional participation
- Dividend yield of 0.21% shows the company maintains a dividend payout policy despite earnings pressure
- Operating in the healthcare/pharma sector which benefits from structural domestic and export demand tailwinds in India
- TTM compounded profit growth of -35% indicates severe earnings deterioration in the most recent period
- TTM compounded sales growth of -14% shows meaningful revenue contraction, not just margin compression
- PE ratio of 36.7x is elevated given that earnings are declining, implying the stock is priced for growth that is not materializing
- Last year ROE dropped to 9% from a 3-year average of 12%, showing declining capital efficiency
- Price-to-book of 3.01x is high relative to the low ROE of 11.9% over 3 years, suggesting stretched valuation on asset basis
- 3-year compounded profit growth of -3% indicates earnings stagnation even over a medium-term horizon
- 3-year compounded sales growth of -2% shows the topline has been essentially flat over three years
- Stock has declined 22% over the past year, reflecting sustained negative market sentiment and potential de-rating
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Aarti Pharmalabs is executing on capacity expansion with a meaningful 60% increase in Xanthine derivatives capacity at Tarapur. No visible headwinds in recent news flow. The trend is constructive as the company invests in growth, though limited news coverage makes it difficult to assess broader operational performance.
- New Tarapur manufacturing block Jun 30
Aarti Pharmalabs inaugurated a new manufacturing block at Tarapur Unit 5, adding 3600 TPA capacity for Xanthine derivatives, bringing total capacity to 9600 TPA.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 | 610 |
| Expenses | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 | 475 |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 | — |
| OPM % | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% | — |
| Other Income | 0 | 1 | 1 | 2 | 2 | 4 | 5 | −2 | 2 | 0 | 2 | 14 | 8 | — |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 | 15 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 | 31 |
| PBT | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 | 95 |
| Tax % | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% | 25% |
| Net Profit | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 | 71 |
| EPS (₹) | 5.2 | 5.72 | 5.82 | 7.2 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.4 | — |
Sep 2026: from the results filed on 28 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,649 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | — | 17% | 18% | 21% | 22% | 20% | 22% |
| Other Income | 0 | 3 | 2 | 5 | 10.12 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| PBT | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | — | 21% | 26% | 28% | 24% | 25% | — |
| Net Profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS (₹) | — | — | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 |
| Div. Payout % | — | 0% | 9% | 13% | 17% | 18% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | 0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 754 |
| Other Liabilities | 0 | 315 | 470 | 540 | 499 | 603 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,437 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 393 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,315 | 1,457 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 0 | −44 | 250 | 216 | 330 | 262 |
| Investing | 0 | −139 | −158 | −215 | −412 | −431 |
| Financing | 0 | 260 | −163 | 10 | 65 | 171 |
| Net Cash Flow | 0 | 78 | −71 | 12 | −17 | 2 |
| Free Cash Flow | 0 | −185 | 130 | 18 | −114 | −186 |
| CFO/EBITDA | — | −11 | 91 | 71 | 85 | 84 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | — | 115 | 84 | 102 | 99 | 117 |
| Inventory Days | — | 272 | 188 | 230 | 199 | 280 |
| Days Payable | — | 123 | 106 | 135 | 94 | 146 |
| Cash Conversion Cycle | — | 264 | 166 | 197 | 204 | 251 |
| Working Capital Days | — | 111 | 94 | 110 | 105 | 90 |
| ROCE % | — | 19% | 16% | 17% | 17% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aarti Pharmalabs insights
68 extracted metrics across FY12–FY27.
Documents
- Concall · Sep 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · Jun 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 9 Oct 2026
- 13 Mar 2026
- 17 Jul 2025
- 17 Mar 2025
- 26 Jun 2024
- General announcements 28 Oct 2026
Frequently Asked Questions about Aarti Pharmalabs
What does Aarti Pharmalabs Ltd do?
Where is Aarti Pharmalabs Ltd (AARTIPHARM) listed?
Which sector does Aarti Pharmalabs Ltd belong to?
What is the PE ratio of Aarti Pharmalabs Ltd?
What is the 52-week high and low of Aarti Pharmalabs Ltd?
Does Aarti Pharmalabs Ltd pay dividends?
What is the Return on Equity (ROE) of Aarti Pharmalabs Ltd?
Company Information
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AARTIPHARM.md for Aarti Pharmalabs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.